In the BioHarmony Drug Report Database
Mogamulizumab-kpkc
Poteligeo (mogamulizumab) is an antibody pharmaceutical. Mogamulizumab was first approved as Poteligeo on 2018-08-08. It is used to treat mycosis fungoides and sezary syndrome in the USA. It has been approved in Europe to treat mycosis fungoides and sezary syndrome. The pharmaceutical is active against C-C chemokine receptor type 4.
Trade Name
|
Poteligeo |
|---|---|
Common Name
|
mogamulizumab |
ChEMBL ID
|
CHEMBL1743041 |
Indication
|
mycosis fungoides, sezary syndrome |
Drug Class
|
Monoclonal antibodies: humanized, immunomodulating |
Image (chem structure or protein)
